Core Insights - NeoGenomics' PanTracer™ LBx test has received coverage from the Centers for Medicare & Medicaid Services' Molecular Diagnostics Services Program [1] Company Summary - NeoGenomics has achieved a significant milestone with the coverage approval for its PanTracer™ LBx test, which is expected to enhance its market position in the molecular diagnostics sector [1]